PHARM TG: what changed
Two financial years side by side, explained: what moved most in the balance sheet and the result, why the result rose or fell, and where the money went.
PHARM TG
Largest movements
- Tangible fixed assets -€33,638
down €33,638 (-5.0%), from €674,785 to €641,148
of which Land and buildings: -€19,624
- Intangible fixed assets -€24,500
down €24,500 (-14.7%), from €166,888 to €142,388
- Stocks and contracts -€12,893
down €12,893 (-10.8%), from €118,925 to €106,032
- Debts after one year -€75,283
down €75,283 (-10.0%), from €754,074 to €678,791
- Gross operating margin -€35,866
down €35,866 (-15.7%), from €229,177 to €193,310
- Staff costs +€11,726
up €11,726 (+15.6%), from €75,012 to €86,738
- Taxes -€10,645
down €10,645 (-90.8%), from €11,721 to €1,077
- Depreciation +€5,380
up €5,380 (+7.0%), from €76,495 to €81,874
- Financial charges -€2,665
down €2,665 (-10.7%), from €24,972 to €22,307
From the 2024 result to the 2025 result
Each bar is the change in one income-statement line, as its effect on the result: higher costs pull it down, higher income lifts it.
Cash bridge derived
Derived from the 2024 and 2025 balance sheets and the 2025 result: not a filed cash-flow statement. It shows where the money came from and went.
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €1,105,342 | €1,014,747 | -€90,594 | -8.2% |
| Fixed assets | 21/28 | €842,174 | €784,036 | -€58,138 | -6.9% |
| Intangible fixed assets | 21 | €166,888 | €142,388 | -€24,500 | -14.7% |
| Tangible fixed assets | 22/27 | €674,785 | €641,148 | -€33,638 | -5.0% |
| Land and buildings | 22 | €637,284 | €617,660 | -€19,624 | -3.1% |
| Furniture and vehicles | 24 | €33,794 | €20,837 | -€12,957 | -38.3% |
| Leasing and similar rights | 25 | €3,708 | €2,651 | -€1,057 | -28.5% |
| Financial fixed assets | 28 | €500 | €500 | = | 0.0% |
| Current assets | 29/58 | €263,168 | €230,711 | -€32,457 | -12.3% |
| Stocks and contracts in progress | 3 | €118,925 | €106,032 | -€12,893 | -10.8% |
| Stocks | 30/36 | €118,925 | €106,032 | -€12,893 | -10.8% |
| Amounts receivable within one year | 40/41 | €32,569 | €23,192 | -€9,377 | -28.8% |
| Trade receivables | 40 | €4,578 | €7,614 | +€3,036 | +66.3% |
| Other amounts receivable | 41 | €27,991 | €15,578 | -€12,413 | -44.3% |
| Cash at bank and in hand | 54/58 | €47,691 | €48,413 | +€722 | +1.5% |
| Deferred charges and accrued income | 490/1 | €63,983 | €53,075 | -€10,909 | -17.0% |
| Total equity and liabilities | 10/49 | €1,105,342 | €1,014,747 | -€90,594 | -8.2% |
| Equity | 10/15 | €151,329 | €149,752 | -€1,577 | -1.0% |
| Contributions | 10/11 | €5,000 | €5,000 | = | 0.0% |
| Profit (loss) carried forward | 14 | €146,329 | €144,752 | -€1,577 | -1.1% |
| Amounts payable | 17/49 | €954,012 | €864,995 | -€89,017 | -9.3% |
| Amounts payable after more than one year | 17 | €754,074 | €678,791 | -€75,283 | -10.0% |
| Financial debts | 170/4 | €754,074 | €678,791 | -€75,283 | -10.0% |
| Amounts payable within one year | 42/48 | €192,726 | €181,017 | -€11,709 | -6.1% |
| Current portion of amounts payable after more than one year | 42 | €78,781 | €80,473 | +€1,692 | +2.1% |
| Trade debts | 44 | €39,340 | €34,701 | -€4,639 | -11.8% |
| Suppliers | 440/4 | €39,340 | €34,701 | -€4,639 | -11.8% |
| Taxes, remuneration and social security | 45 | €34,986 | €35,017 | +€31 | +0.1% |
| Taxes | 450/3 | €17,499 | €16,395 | -€1,103 | -6.3% |
| Remuneration and social security | 454/9 | €17,487 | €18,621 | +€1,134 | +6.5% |
| Other amounts payable | 47/48 | €39,619 | €30,827 | -€8,792 | -22.2% |
| Accrued charges and deferred income | 492/3 | €7,212 | €5,187 | -€2,025 | -28.1% |
| Remuneration, social security and pensions | 62 | €75,012 | €86,738 | +€11,726 | +15.6% |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets | 630 | €76,495 | €81,874 | +€5,380 | +7.0% |
| Other operating charges | 640/8 | €3,598 | €3,800 | +€202 | +5.6% |
| Non-recurring operating charges | 66A | €20 | - | -€20 | |
| Gross operating margin | 9900 | €229,177 | €193,310 | -€35,866 | -15.7% |
| Operating profit (loss) | 9901 | €74,052 | €20,898 | -€53,154 | -71.8% |
| Financial income | 75/76B | €3,124 | €908 | -€2,216 | -70.9% |
| Recurring financial income | 75 | €2,807 | €821 | -€1,985 | -70.7% |
| Non-recurring financial income | 76B | €318 | €87 | -€231 | -72.6% |
| Financial charges | 65/66B | €24,972 | €22,307 | -€2,665 | -10.7% |
| Recurring financial charges | 65 | €24,972 | €22,307 | -€2,665 | -10.7% |
| Profit (loss) for the period before taxes | 9903 | €52,204 | -€500 | -€52,704 | |
| Income taxes | 67/77 | €11,721 | €1,077 | -€10,645 | -90.8% |
| Profit (loss) for the period | 9904 | €40,483 | -€1,577 | -€42,060 | |
| Profit (loss) for the period to be appropriated | 9905 | €40,483 | -€1,577 | -€42,060 |
Source: filed annual accounts (NBB), financial years ended 31 December 2024 and 31 December 2025. Colour: green is a favourable move for that line, red an unfavourable one. Prepared on 11 October 2026 via checked.be.